Dr. Yanagiya from ARCALIS, Inc.’s business development department will present a poster at the 5th Tsukuba Kyoso-no-Ba conference.
Dr. Yanagiya from ARCALIS, Inc.’s business development department will present a poster at the 5th Tsukuba Kyoso-no-Ba conference on Tuesday, March 3rd, 2026, at Astellas Pharma Inc. Tsukuba Research Center. We cordially invite all conference participants to visit the poster.
【Event details】
Date: March 3rd (Tue), 2026
Venue: Astellas Pharma Inc. Tsukuba Research Center
【Poster presentation】
Title: ARCALIS: An integrated CDMO advancing mRNA therapeutics for the treatment of rare diseases from mRNA design to manufacturing
Time: From 4:45PM to 6:50PM
Presenter: Dr. Akiko Yanagiya
【Abstract】ARCALIS provides integrated services from mRNA design to large‑scale GMP manufacturing as a CDMO specializing in mRNA therapeutics including vaccines for infectious diseases and cancer, which is also potential modality for treating rare diseases. mRNA therapeutics enable rapid development, flexible design for tailored treatment strategies, making them particularly valuable to cure rare diseases, in which conventional therapeutic methods are limited. Currently, mRNA therapeutics aimed at treating rare diseases have already advanced to clinical trials in fields such as genome editing and enzyme replacement therapy. In this poster presentation, we introduce three proprietary technologies developed by ARCALIS that enhance the high‑quality manufacturing of mRNA therapeutics to advance the development of treatments for rare diseases: (1) An organ‑selective mRNA delivery platform using optimized lipid compositions, (2) An innovative codon optimization method based on mRNA stability prediction model by machine learning, named HARNATM, developed in collaboration with Hitachi, Inc., and (3) Our original saRNA platform enabling efficient and sustained protein expression.. These technologies enable the production of more efficient and safer mRNA therapeutics to treat rare diseases.